Econic Biosciences

Econic Biosciences is a private, preclinical-stage biotech focused on developing first-in-class therapeutics targeting extrachromosomal DNA (ecDNA), a potent driver of tumor heterogeneity and drug resistance found in up to one-third of cancers. The company is built on foundational research from its scientific founders and is led by an experienced executive team with deep oncology and drug development expertise from major pharma and biotech. Econic's approach aims to identify and inhibit key molecular pathways essential for ecDNA genesis, replication, or maintenance, offering a potential new modality to treat cancers with poor prognoses.

Integrated discovery platform focused on identifying and validating novel therapeutic targets within the extrachromosomal DNA (ecDNA) lifecycle (genesis, replication, segregation, maintenance). Utilizes computational biology, functional genomics, and proprietary models to find cancer-specific vulnerabilities.

The direct competitive landscape for ecDNA-targeted therapies is currently sparse, representing a blue-ocean opportunity. However, the field is gaining attention through initiatives like Cancer Grand Challenges, which may spur new entrants. Indirect competition comes from all existing oncology therapies, and success would likely attract rapid competition from large pharma.